Reading TYRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TYRA free→Reading TYRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TYRA free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed because the company was unprofitable over the past year. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $28.55. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.78x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.57 → $-0.64 (-11.5% / 30d). 1 raised, 8 cut, 14 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 93% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$221.
How much price usually moves either way.
On a bad day, this stock has moved -$479.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,582.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for TYRA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 13, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TYRA Tyra Biosciences, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Management aims to report initial three-month complete response data from both dose cohorts in August 2026.
Newly stated in 2026-Q1. Management has set a target to report initial three-month complete response data from both dose cohorts in August 2026. No financial data directly supports or contradicts this timeline yet.
“We expect to report initial three-month complete response data from both dose cohorts in August 2026.”
Management plans to release initial results from the safety sentinel cohort, including safety data, by the fourth quarter of 2026.
Newly stated in 2026-Q1. Management expects to release initial results from the safety sentinel cohort by Q4 2026. Current financials do not provide direct evidence of progress towards this milestone.
“The study remains on track, with initial results from the safety sentinel cohort expected in the fourth quarter of this year.”
Management believes 2026 will be a pivotal year for the company, indicating significant developments or milestones.
Newly stated in 2025-Q3. Management anticipates 2026 as a pivotal year for TYRA, suggesting key developments. However, financials show a net income decline from -$25.57M in 2024-Q4 to -$39.31M in 2026-Q1, indicating financial challenges.
“We believe 2026 will be a pivotal year for TYRA.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 16, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the Board) of Tyra Biosciences, Inc. (the Company), and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in the number of authorized directors from nine to ten and appointed Habib J. Da…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company’s principal accounting officer, succeeding Alan Fuhrman, the Company’s Chief Financial Officer, in that role, each effective as of April 1, 2026. Mr. Fuhrman continues to be the Company’s pri…
Results of Operations and Financial Condition. On March 2, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchan…
Other Events. On March 4, 2026, Tyra Biosciences, Inc. (the “Company”) agreed to issue and sell 4,000,000 shares of common stock to a large investment management firm at a purchase price of $31.50 per share. The Company expects to receive $126.0 million in gross proceeds upon settlement, before deducting fees and other expenses payable by it. The shares of common stock are being issued as a block transaction under the Company’s “at-the-market” offering program, which has been registered under…